Previous studies showed that for those with a PD-L1 tumor proportion score (TPS) of at least 50%, the addition of chemotherapy to pembrolizumab significantly improved objective response rate (ORR) and progression-free survival (PFS), though at the cost of increased treatment-related adverse effects (TRAEs). The gene discussed is CD274; the disease is neoplasm.